Corrections: Genetic sequencing for surveillance of drug resistance in tuberculosis in highly endemic countries: a multi-country population-based surveillance study (The Lancet Infectious Diseases (2018) (S1473309918300732) (10.1016/S1473-3099(18)30073-2));Genetic sequencing for surveillance of drug resistance in tuberculosis in highly endemic countries: a multi-country population-based surveillance study

The Lancet Infectious Diseases

Volumn 18, Issue 6, 2018, Pages 675-683

  Zignol, Matteo ^a   Cabibbe, Andrea Maurizio ^a,b   Dean, Anna S ^a   Glaziou, Philippe ^a   Alikhanova, Natavan ^c   Ama, Cecilia ^d   Andres, Sönke ^e   Barbova, Anna ^f   Borbe Reyes, Angeli ^d   Chin, Daniel P ^g   Cirillo, Daniela Maria ^b   Colvin, Charlotte ^h   Dadu, Andrei ^a   Dreyer, Andries ⁱ   Driesen, Michèle ^j   Gilpin, Christopher ^a   Hasan, Rumina ^k   Hasan, Zahra ^k   Hoffner, Sven ^l   Hussain, Alamdar ^m   Ismail, Nazir ^i,n   Kamal, S M Mostofa ^o   Khanzada, Faisal Masood ^m   Kimerling, Michael ^p   Kohl, Thomas Andreas ^e   Mansjö, Mikael ^q   Miotto, Paolo ^b   Mukadi, Ya Diul ^h   Mvusi, Lindiwe ^r   Niemann, Stefan ^e   Omar, Shaheed V ⁱ   Rigouts, Leen ^j,s   Schito, Marco ^t   Sela, Ivita ^u   Seyfaddinova, Mehriban ^c   Skenders, Girts ^u   Skrahina, Alena ^v   Tahseen, Sabira ^m   Wells, William A ^h   Zhurilo, Alexander ^w   Weyer, Karin ^a   Floyd, Katherine ^a   Raviglione, Mario C ^a   more..

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c Research Scientific Institute of Lung Diseases   (Azerbaijan)

^d STD AIDS Cooperative Central Laboratory   (Philippines)

^e RESEARCH CENTER BORSTEL   (Germany)

^f Ministry of Health of Ukraine   (Ukraine)

^g BILL AND MELINDA GATES FOUNDATION   (United States)

^h UNITED STATES AGENCY FOR INTERNATIONAL DEVELOPMENT   (United States)

ⁱ NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^j INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^k AGA KHAN UNIVERSITY   (Pakistan)

^l KAROLINSKA INSTITUTE   (Sweden)

^m National Tuberculosis Control Programme   (Pakistan)

ⁿ UNIVERSITY OF PRETORIA   (South Africa)

^o National Institute of Diseases of Chest and Hospital   (Bangladesh)

^p KNCV TUBERCULOSIS FOUNDATION   (Netherlands)

^q SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^r NATIONAL DEPARTMENT OF HEALTH   (South Africa)

^s UNIVERSITY OF ANTWERP   (Belgium)

^t CRITICAL PATH INSTITUTE   (United States)

^u RIGA EAST UNIVERSITY HOSPITAL   (Latvia)

^v Republican Scientific and Practical Center for Pulmonology and Tuberculosis   (Belarus)

^w STATE INSTITUTION NATIONAL RESEARCH CENTER FOR RADIATION MEDICINE OF THE NATIONAL ACADEMY OF MEDICAL SCIENCES OF UKRAINE   (Ukraine)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; BACTERIAL PROTEIN; CAPREOMYCIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; FABG PROTEIN; INHA PROTEIN; ISONIAZID; ISONIAZID PLUS RIFAMPICIN; KANAMYCIN; KATG PROTEIN; MOXIFLOXACIN; OFLOXACIN; PNCA PROTEIN; PYRAZINAMIDE; RIFAMPICIN; RNA POLYMERASE BETA SUBUNIT; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; BACTERIAL DNA;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; AZERBAIJAN; BACTERIUM ISOLATE; BANGLADESH; BELARUS; CONTROLLED STUDY; GENE SEQUENCE; HUMAN; MAJOR CLINICAL STUDY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PAKISTAN; PHILIPPINES; PRIORITY JOURNAL; PROMOTER REGION; SOUTH AFRICA; TUBERCULOSIS; UKRAINE; ASIA; DRUG EFFECT; ENDEMIC DISEASE; EUROPE; GENETICS; GLOBAL HEALTH; HEALTH SURVEY; MICROBIOLOGY; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT TUBERCULOSIS;

ANTITUBERCULAR AGENTS; ASIA; DNA, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENDEMIC DISEASES; EUROPE; GLOBAL HEALTH; HUMANS; MYCOBACTERIUM TUBERCULOSIS; POPULATION SURVEILLANCE; SOUTH AFRICA; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 85044251701     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(18)30227-5     Document Type: Erratum

References (31)

1. WHO. Antimicrobial resistance: global report on surveillance 2014. http://www.who.int/drugresistance/documents/surveillancereport/en/, April, 2014 (accessed Dec 29, 2017).
2. WHO. Global tuberculosis report 2017. http://www.who.int/tb/publications/global_report/en/, 2017 (accessed Dec 29, 2017).
3. Zignol, M, Dean, AS, Falzon, D, et al. Twenty years of global surveillance of antituberculosis-drug resistance. N Engl J Med 375 (2016), 1081–1089.
4. Uplekar, M, Weil, D, Lonnroth, K, et al. WHO's new end TB strategy. Lancet 385 (2015), 1799–1801.
5. Denkinger, CM, Dolinger, D, Schito, M, et al. Target product profile of a molecular drug-susceptibility test for use in microscopy centers. J Infect Dis 211:suppl 2 (2015), S39–S49.
6. Miotto, P, Tessema, B, Tagliani, E, et al. A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis. Eur Respir J, 50, 2017, 1701354.
7. Farhat, MR, Sultana, R, Iartchouk, O, et al. Genetic determinants of drug resistance in Mycobacterium tuberculosis and their diagnostic value. Am J Respir Crit Care Med 194 (2016), 621–630.
8. Walker, TM, Kohl, TA, Omar, SV, et al. Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study. Lancet Infect Dis 15 (2015), 1193–1202.
9. Alikhanova, N, Akhundova, I, Seyfaddinova, M, et al. First national survey of anti-tuberculosis drug resistance in Azerbaijan and risk factors analysis. Public Health Action 4:suppl 2 (2014), S17–S23.
10. Kamal, SMM, Hossain, A, Sultana, S, et al. Anti-tuberculosis drug resistance in Bangladesh: reflections from the first nationwide survey. Int J Tuberc Lung Dis 19 (2015), 151–156.
11. Skrahina, A, Hurevich, H, Zalutskaya, A, et al. Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk. Eur Respir J 39 (2012), 1425–1431.
12. Tahseen, S, Qadeer, E, Khanzada, FM, et al. Use of Xpert(®) MTB/RIF assay in the first national anti-tuberculosis drug resistance survey in Pakistan. Int J Tuberc Lung Dis 20 (2016), 448–455.
13. Lim, DR, Dean, AS, Taguinod-Santiago, MR, et al. Low levels of fluoroquinolone resistance among patients with tuberculosis in the Philippines: results of a national survey. Eur Respir J, 2018 published online March 1. DOI: 10.1183/13993003.02571-2017.
14. National Institute for Communicable Diseases. South African tuberculosis drug resistance survey 2012–2014. http://www.nicd.ac.za/index.php/centres/centre-for-tuberculosis/population-researchsurvey/, March 24, 2017 (accessed Dec 29, 2017).
15. Pavlenko, E, Barbova, Hovhannesyan, A, et al. Alarming levels of multidrug-resistant tuberculosis in Ukraine: results from the first national survey. Int J Tuberc Lung Dis 22 (2018), 197–205.
16. WHO. Guidelines for surveillance of drug resistance in tuberculosis. 5th edn. http://www.who.int/tb/publications/2015/drs_guidelines/en/, June, 2015 (accessed Dec 29, 2017).
17. Zignol, M, Dean, AS, Alikhanova, N, et al. Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project. Lancet Infect Dis 16 (2016), 1185–1192.
18. Zhang, Y, Yew, WW, Mechanisms of drug resistance in Mycobacterium tuberculosis: update 2015. Int J Tuberc Lung Dis 19 (2015), 1276–1289.
19. Plummer M. JAGS: a program for analysis of Bayesian graphical models using Gibbs sampling. Proceedings of the 3rd international workshop on distributed statistical computing; Technische Universit, Vienna, Austria; March 20–22, 2003. 125.
20. Rényi, A, Probability theory. 2007, Dover Publications Inc, New York.
21. Van Deun, A, Aung, KJM, Bola, V, et al. Rifampin drug resistance tests for tuberculosis: challenging the gold standard. J Clin Microbiol 51 (2013), 2633–2640.
22. Ramirez-Busby, SM, Valafar, F, Systematic review of mutations in pyrazinamidase associated with pyrazinamide resistance in Mycobacterium tuberculosis clinical isolates. Antimicrob Agents Chemother 59 (2015), 5267–5277.
23. Whitfield, MG, Warren, RM, Streicher, EM, et al. Mycobacterium tuberculosis pncA polymorphisms that do not confer pyrazinamide resistance at a breakpoint concentration of 100 micrograms per milliliter in MGIT. J Clin Microbiol 53 (2015), 3633–3635.
24. Ängeby, K, Juréen, P, Kahlmeter, G, Hoffner, SE, Schön, T, Challenging a dogma: antimicrobial susceptibility testing breakpoints for Mycobacterium tuberculosis. Bull World Health Organ 90 (2012), 693–698.
25. Rigouts, L, Nolasco, O, de Rijk, P, et al. Newly developed primers for comprehensive amplification of the rpoB gene and detection of rifampin resistance in Mycobacterium tuberculosis. J Clin Microbiol 45 (2007), 252–254.
26. Pankhurst, LJ, Del Ojo Elias, C, Votintseva, AA, et al. Rapid, comprehensive, and affordable mycobacterial diagnosis with whole-genome sequencing: a prospective study. Lancet Respir Med 4 (2016), 49–58.
27. McNerney, R, Clark, TG, Campino, S, et al. Removing the bottleneck in whole genome sequencing of Mycobacterium tuberculosis for rapid drug resistance analysis: a call to action. Int J Infect Dis 56 (2017), 130–135.
28. Starks, AM, Avilés, E, Cirillo, DM, et al. Collaborative effort for a centralized worldwide tuberculosis relational sequencing data platform. Clin Infect Dis 61:suppl 3 (2015), S141–S146.
29. Walker, TM, Merker, M, Kohl, TA, Crook, DW, Niemann, S, Peto, TEA, Whole genome sequencing for M/XDR tuberculosis surveillance and for resistance testing. Clin Microbiol Infect 23 (2017), 161–166.
30. WHO. Updated interim critical concentrations for first-line and second-line DST. http://www.stoptb.org/wg/gli/assets/documents/Updated%20critical%20concentration%20table_1st%20and%202nd%20line%20drugs.pdf, May, 2012 (accessed Dec 29, 2017).
31. Phelan, J, O'Sullivan, DM, Machado, D, et al. The variability and reproducibility of whole genome sequencing technology for detecting resistance to anti-tuberculous drugs. Genome Med, 8, 2016, 132.